Subsidy Information and Financing Scheme MSHLRipretinib Tablet 50 mg Treatment of patients with advanced gastrointestinal stromal tumours (GIST) who have received prior... See all × MSHLRipretinib Tablet 50 mg Treatment of patients with advanced gastrointestinal stromal tumours (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 50 mg National Cancer Centre